and Novo Nordisk A/S (WNCN-P43336, P.E.)
This design enables three distinct pharmacological actions in a single molecule: GLP-1 receptor agonism : The two conjugated GLP-1 analog peptides activate GLP-1R to produce appetite suppression, glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying GIP receptor antagonism : The antibody component blocks GIP signaling, which may reduce fat storage and modify energy metabolism Extended half-life : The antibody backbone provides a half-life of approximately 21 days -- three times longer than any approved weekly incretin therapy -- enabling once-monthly dosing The GIP antagonism approach is the most distinctive feature
It also slows the rate at which the stomach empties into the intestine, regulates the release of insulin from the pancreas, and seems to boost lipid metabolism, which can help lower cholesterol
This concentration enables convenient dosing with standard insulin syringes where 0.1ml (10 units) delivers 0.5mg
Do not switch forms or release types unless a healthcare professional has instructed that change
Only a lawyer can tell you if you have a case
